Clinical trial
Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly…
NCT00220103 · Royal Marsden NHS Foundation Trust, Other · Completed
Key facts
| NCT number | NCT00220103 |
|---|---|
| Title | Pre-operative Epirubicin, Cisplatin, and Capecitabine in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma |
| Official title | Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma |
| Lead sponsor | Royal Marsden NHS Foundation Trust, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Adenocarcinoma of Oesophagus |
| Intervention type | Drug, Procedure |
| Interventions | epirubicin, capecitabine, cisplatin, Surgical resection |
| Enrollment | 80 |
| Start date | Nov 1, 2002 |
| First posted | Sep 22, 2005 |
| Last update posted | Dec 16, 2009 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: